Myriad Genetics (MYGN) to Launch AI-Enhanced Prostate Cancer Test

Myriad Genetics Inc. (MYGN) announced on May 27, 2026, it will launch Prolaris-AI, an artificial intelligence-driven test for prostate cancer prognosis. The new diagnostic integrates machine learning with gene expression analysis to generate a more precise risk score, helping to distinguish aggressive disease from indolent cases, the company said. The launch represents an upgrade to Myriad's existing Prolaris platform and aims to improve treatment decisions for men newly diagnosed with prostate cancer. The Salt Lake City-based company expects the test to be available to U.S. patients in the third quarter of 2026. Myriad shares have risen 12% year-to-date, fueled by growing investor enthusiasm for AI applications in precision medicine.